It’s been nearly a decade since the first CAR-T cancer cell therapy was approved by the FDA, offering a powerful and durable­ ­therapy against tumours. But when it comes to fighting solid tumours, CAR ...

London-based Big Picture Bio has launched with £2.2 million (€2.6 million) in funding to build an AI platform that designs drug combinations for cancer, starting largely with medicines that are ...

Novartis has licensed an undisclosed preclinical radioligand therapy from China’s BoomRay Pharmaceuticals in a deal worth up to $900 million (€786 million), adding another asset to one of the pharma ...

Boehringer Ingelheim has partnered with New York-based Envisagenics to hunt for new targets in hard-to-treat solid tumors, opening up more than $1 billion (€873 million) in potential payments.

Belgian biotech Remynd has secured a €3.5 million investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to move ...

UK biotech Mestag Therapeutics has raised $40 million and appointed veteran drug developers Lindsey Rolfe as chief medical officer and Pascal Merchiers as chief development officer, as the company ...

Australian radiopharma company Telix Pharmaceuticals has agreed to acquire Munich-based ITM Isotope Technologies for an ...

New data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its ...

Beacon Therapeutics' gene therapy laru-zova met its U.S. pivotal endpoint in X-linked retinitis pigmentosa, while results on the trial's separately designated European primary efficacy measure were ...

Novartis has stopped developing its TREM2 antibody VHB937 (lifonebart) in amyotrophic lateral sclerosis (ALS) after the ...

The European Investment Bank (EIB) is providing German Ethris with €30 million to advance clinical development of its ...

Belgian techbio Sightera Biosciences has raised €3 million in pre-seed financing to expand its AI drug discovery platform and advance a pipeline of small molecules in oncology and fibrosis. Why it ...